XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 44.47

Change

+0.03 (+0.07)%

Market Cap

N/A

Volume

0.03M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-25 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.27 (+0.86%)

USD 37.71B
FHLC Fidelity® MSCI Health Care In..

+0.32 (+0.46%)

USD 2.77B
FXH First Trust Health Care AlphaD..

+0.39 (+0.35%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

-0.56 (-0.62%)

USD 0.20B
IDNA iShares Genomics Immunology an..

-0.18 (-0.79%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.81 (-2.55%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+0.41 (+0.42%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.25 (-0.84%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-1.01 (-1.61%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.54 (-2.58%)

USD 6.67M

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A
MSSS Northern Lights Fund Trus.. 10.03 % 0.00 %

-0.13 (-0.46%)

USD 0.11B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.44% 43% F 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.44% 43% F 66% D+
Trailing 12 Months  
Capital Gain -2.24% 33% F 28% F
Dividend Return 1.49% 100% F 26% F
Total Return -0.75% 33% F 23% F
Trailing 5 Years  
Capital Gain 6.77% 24% F 46% F
Dividend Return 6.17% 68% D+ 15% F
Total Return 12.94% 29% F 35% F
Average Annual (5 Year Horizon)  
Capital Gain -2.00% 19% F 23% F
Dividend Return -1.22% 29% F 15% F
Total Return 0.77% 68% D+ 19% F
Risk Return Profile  
Volatility (Standard Deviation) 15.70% 62% D 65% D
Risk Adjusted Return -7.80% 19% F 16% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.